These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 31165505)

  • 1. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
    Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
    Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
    Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C
    J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
    Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
    Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
    Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
    Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G; Özekinci S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
    Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
    Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.
    Andrici J; Sheen A; Sioson L; Wardell K; Clarkson A; Watson N; Ahadi MS; Farzin M; Toon CW; Gill AJ
    Mod Pathol; 2015 Oct; 28(10):1360-8. PubMed ID: 26226841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.